Stocks Health care ENOV
NYSE · Health careEnovis CORP (ENOV)
Enovis CORP brought in $2.3B of revenue over the twelve months to October 2, 2026, up 3.3% from a year earlier. It posted a net loss of $527.4M. Operating cash flow minus capital spending left $19.9M of free cash flow in fiscal 2025. At October 2, 2026 it held $13M in cash against $1.3B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Enovis CORP
- Net worth
- Enovis CORP has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $1.5B on its balance sheet at October 2, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.2B (+6.7% year on year), with a net loss of $1.2B. Over the 12 months to October 2, 2026: revenue $2.3B, net loss $527.4M.
- Cash flow
- In fiscal 2025 operations brought in $217.3M of cash; after $197.4M of capital spending, free cash flow was $19.9M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to October 2, 2026. Open on SEC EDGAR
- Next earnings report
- Enovis CORP's next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Enovis CORP does
Enovis CORP is registered with the SEC under industry code SIC 3842 (Orthopedic, Prosthetic & Surgical Appliances & Supplies). Its shares trade on NYSE under the ticker ENOV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.2B | -$1.2B | -$20.75 | $19.9M |
| 2024 | $2.1B | -$825.5M | -$14.93 | -$67.2M |
| 2023 | $1.7B | -$33.3M | -$0.61 | $12.8M |
| 2022 | $1.6B | -$13.3M | -$0.25 | -$161.3M |
| 2021 | $1.4B | $71.7M | $1.40 | $251.9M |
| 2020 | $1.1B | $42.6M | $0.93 | $187.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ENOV ranks in Health care
Dividends
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2012 | n/a | $0 | n/a |
| 2011 | n/a | $0 | n/a |
| 2011 | n/a | $205K | n/a |
Latest SEC filings
What Enovis CORP has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to October 2, 2026Revenue rose 1.8% to $558.7M versus the same quarter last year; diluted EPS $0.06 versus -$9.99.
- November 5, 2026
- September 1, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026Quarterly report 10-Q · period to July 3, 2026Revenue rose 3.2% to $582.8M versus the same quarter last year; diluted EPS -$0.02 versus -$0.64.
- August 6, 2026
- July 28, 2026Passive stake changed SCHEDULE 13G/A
- July 8, 2026Passive stake changed SCHEDULE 13G/A
- June 26, 2026
- May 28, 2026
What is ENOV worth? A DCF from its reported cash flow
Insider trades
What the people running Enovis CORP did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $449.6K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 30, 2026 | Ortiz ChristineDirector | Received as pay | 958 | - |
| September 4, 2026 | Engert OliverChief Administrative Officer | Bought | 2,660 | $50K |
| September 4, 2026 | McDonald DamienChief Executive Officer, Director | Bought | 13,035 | $249.6K |
| September 3, 2026 | Engert OliverChief Administrative Officer | Bought | 5,140 | $100K |
| September 2, 2026 | Engert OliverChief Administrative Officer | Bought | 2,458 | $49.9K |
| June 30, 2026 | Ortiz ChristineDirector | Received as pay | 846 | - |
| June 15, 2026 | Engert OliverChief Administrative Officer | Bought | 1,000 | $20.9K |
| June 11, 2026 | Engert OliverChief Administrative Officer | Received as pay | 1,000 | $21K |
Who owns ENOV
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| American Century Investment Management, Inc.13G, passive with 3 related filers | 10.6% | July 8, 2026 |
| Vanguard Portfolio Management13G, passive | 6.82% | April 29, 2026 |
| Rubric Capital Management LP13G, passive with 1 related filers | 6.78% | August 14, 2026 |
| Vanguard Capital Management13G, passive | 5.23% | April 29, 2026 |
| Diamond Hill Capital Management Inc13G, passive | 5% | February 6, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 253 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 10,295,666 | +359,197 |
| American Century Companies Inc | 6,106,561 | +1,337,640 |
| Vanguard Portfolio Management LLC | 3,926,268 | +117,639 |
| Rubric Capital Management LP | 3,900,000 | +1,446,735 |
| Vanguard Capital Management LLC | 2,484,318 | -68,033 |
| State Street Corp | 2,462,788 | +60,553 |
| DAVENPORT & Co LLC | 2,341,521 | -96,720 |
| Hood River Capital Management LLC | 2,299,326 | +542,657 |
| Fmr LLC | 2,208,811 | +846,214 |
| Goldman Sachs Group Inc | 1,772,577 | +204,429 |
| Dimensional Fund Advisors LP | 1,744,917 | -801,005 |
| Geode Capital Management, LLC | 1,496,218 | +126,304 |
| Paradigm Capital Management Inc | 1,378,398 | -398,317 |
| Private Management Group Inc | 1,365,082 | +381,705 |
| UBS Group AG | 1,247,409 | +425,503 |
| River Road Asset Management, LLC | 1,180,107 | -322,875 |
| Morgan Stanley | 1,069,661 | +37,771 |
| Allspring Global Investments Holdings, LLC | 1,041,277 | -4,083 |
| Charles Schwab Investment Management Inc | 998,634 | -14,910 |
| Millennium Management LLC | 803,315 | +173,999 |
Insiders
18 insiders reported holding 1,306,812 shares in total, about $36.2M at the last price.
| Holder | Shares |
|---|---|
| McDonald DamienChief Executive Officer, Director | 247,077 |
| Pryor Daniel AFormer EVP, Strategy & Bus Dev | 160,449 |
| Berry Phillip Benjamin (Ben)SVP, Chief Financial Officer | 150,822 |
| Shirley BradyDirector | 110,589 |
| Lang Patricia ASVP, Chief HR Officer | 75,703 |
| Vogt LouisGROUP PRESIDENT, RECON | 68,875 |
| Ross Terry DGROUP PRESIDENT, P&R | 68,477 |
| Tandy Bradley JSVP and Chief Legal Officer | 65,641 |
| Engert OliverChief Administrative Officer | 63,898 |
| Perfall A ClaytonDirector | 54,190 |
Questions about ENOV
What does Enovis CORP do?
Enovis CORP is a company in the Health care sector, listed on NYSE as ENOV. Its shares trade on NYSE under the ticker ENOV.
What is Enovis CORP's net worth?
Enovis CORP has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $1.5B on its balance sheet at October 2, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Enovis CORP profitable?
No. Over the twelve months to October 2, 2026 it reported a net loss of $527.4M on revenue of $2.3B.
How much revenue does Enovis CORP make?
Over the twelve months to October 2, 2026 Enovis CORP reported revenue of $2.3B. That is 3.3% more than a year earlier.
When did Enovis CORP last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to October 2, 2026.
When is Enovis CORP's next earnings report?
Enovis CORP's next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ENOV with
Follow ENOV
Get an email when Enovis CORP files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Enovis CORP tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.